Relmada Therapeutics Provides Corporate Update
- None.
- None.
Insights
The strategic update from Relmada Therapeutics indicates a robust pipeline with significant clinical milestones on the horizon for 2024, particularly regarding their flagship product, REL-1017, for major depressive disorder (MDD). The financial health of a biotech firm is closely tied to its clinical progress, as each phase passed can potentially increase the company's value. Relmada's emphasis on a strong balance sheet to support upcoming milestones is crucial, as clinical trials are capital-intensive. The company's ability to fund operations through the entirety of 2024 without additional capital infusion is a positive signal to investors, potentially reducing dilution risk. The successful optimization of clinical development plans and the progression of enrollment in pivotal trials are key drivers for future valuation. Moreover, the development of a non-psychedelic psilocybin program could diversify the company's portfolio, addressing a separate market with its own set of regulatory and commercial challenges.
Relmada's progress in clinical trials, particularly the Phase 3 program for REL-1017, is a significant indicator of the company's potential to bring new treatments to market. The adjustments made to study protocols and patient adjudication processes suggest a proactive approach to overcoming common hurdles in clinical research, such as patient recruitment and retention. The enrollment status of study 302 at 50% is a tangible milestone, offering a timeline for when the market might expect results. Furthermore, the completion of pre-clinical and Phase 1 studies for REL-1017 positions the company closer to a New Drug Application (NDA) filing, signaling the transition from a developmental to a potentially commercial stage. The initiation of a Phase 1 trial for a modified-release psilocybin formulation indicates an expansion into a new therapeutic area, which could have implications for the treatment of steatotic liver disease and obesity, areas with significant unmet medical needs.
The CNS therapeutic area, particularly MDD, represents a market with a high prevalence and an ongoing demand for innovative treatments. Relmada's positioning within this space, especially with REL-1017, could capture a significant market share if clinical outcomes are favorable. The strategic reorganization of the clinical team and the optimization of study protocols are likely responses to market demands for efficiency and effectiveness in drug development. The anticipation of multiple clinical milestones in 2024 suggests that the company is nearing critical inflection points that could greatly influence its market positioning. Additionally, the foray into metabolic psilocybin therapy could tap into the growing interest in psychedelic compounds for various indications, potentially opening up new market opportunities and partnerships.
Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated
Relmada's Strong Balance Sheet to Support the Company Through All of 2024's Expected Critical Catalysts
"We made significant operational progress throughout our business in 2023 and believe we are well-positioned for making 2024 the pivotal and most important year for Relmada to date," said Sergio Traversa, Relmada's Chief Executive Officer. "In our ongoing Phase 3 program for REL-1017 as an adjunctive treatment for major depressive disorder (MDD), we completed a thorough analysis of the study 301 and study 303 results, and subsequently made important revisions to our clinical development plan, including optimizing the study protocols, improving the patient adjudication process, enhancing the site engagement strategy, and reorganizing our clinical team to better align with the ongoing study 302 and study 304 clinical study operations requirements. Importantly, study 302 is now approximately
"In addition, we advanced our valuable non-psychedelic/low dose metabolic psilocybin program, which showed significant therapeutic potential on multiple parameters in pre-clinical rodent studies," continued Mr. Traversa. "Looking ahead, we have multiple clinical development milestones expected in 2024, for both REL-1017 and our non-psychedelic/modified-release psilocybin program, and we expect our cash runway to extend beyond all of these anticipated catalysts."
We would like to thank our outgoing Chief Medical Officer, Dr. Cedric O'Gorman, for his contribution in the optimization of the clinical development strategy for the REL 1017 studies 302 and 304. We also welcome Dr. Andrew Cutler as Senior Clinical Development Advisor, who will help Relmada through the completion of the REL-1017 Phase 3 program and the NDA/approval process.
Upcoming Anticipated Milestones
- Complete enrollment in REL-1017 study 302 (Reliance II), which is planned to enroll approximately 300 patients, in the first half of 2024.
- Complete enrollment in REL 1017 study 304 (Relight), which is planned to enroll approximately 300 patients, by year-end 2024.
- Commence a Phase 1 trial in obese patients with steatotic liver disease in the first half of 2024 to define the pharmacokinetic, safety and tolerability profile of the Company's modified-release psilocybin formulation (REL-P11), followed by a Phase 2a trial to establish clinical proof-of-concept with data expected in the first half of 2025.
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.
About REL-P11
Relmada acquired the development and commercial rights to a novel psilocybin and derivatives program in July of 2021. Psilocybin has neuroplastogen™ effects that have the potential to ameliorate neurodegenerative conditions. The pleiotropic metabolic effects of low-dose psilocybin were discovered while studying its neuroplastogen™ potential in a rodent model deficient in neurogenesis – obese rats maintained on a high fructose, high fat diet (HFHFD), and were then replicated in mice.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully initiated and carried out, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-provides-corporate-update-302026193.html
SOURCE Relmada Therapeutics, Inc.
FAQ
What are the anticipated milestones for Relmada Therapeutics, Inc. (RLMD) in 2024?
What progress has been made in the ongoing Phase 3 program for REL-1017?
What advancements have been made in Relmada's non-psychedelic/low dose metabolic psilocybin program?
What is the purpose of the Phase 1 trial in obese patients with steatotic liver disease?
